![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/07/24/2918356/0/en/TransCode-Therapeutics-Inc-Announces-Closing-of-Public-Offering.html
https://www.globenewswire.com/news-release/2024/07/23/2916919/0/en/TransCode-Therapeutics-Inc-Announces-Pricing-of-Public-Offering.html
https://www.globenewswire.com/news-release/2024/07/22/2916837/0/en/TransCode-Therapeutics-Inc-Announces-Proposed-Public-Offering-of-Common-Stock.html
https://www.globenewswire.com/news-release/2024/06/10/2895871/0/en/Nasdaq-Determines-That-TransCode-Therapeutics-Has-Regained-Compliance-with-Continued-Listing-Requirements.html
https://www.globenewswire.com/news-release/2024/05/29/2889976/0/en/TransCode-Therapeutics-Reports-Positive-Data-from-First-in-Human-Clinical-Study-Using-Novel-Lead-Therapeutic-Candidate-TTX-MC138.html
https://www.globenewswire.com/news-release/2024/05/13/2880453/0/en/TransCode-Therapeutics-Open-Letter-to-Shareholders.html
https://www.globenewswire.com/news-release/2024/04/15/2862824/0/en/TransCode-Therapeutics-Announces-FDA-Clearance-To-Initiate-Phase-1-2-Clinical-Trial-with-TTX-MC138-in-Patients-with-Advanced-Solid-Tumors.html
https://www.globenewswire.com/news-release/2024/04/03/2857023/0/en/TransCode-Therapeutics-Reports-2023-Results-Provides-Business-Update.html
https://www.globenewswire.com/news-release/2024/03/28/2853993/0/en/TransCode-Therapeutics-Announces-Appointment-of-Daniel-Vlock-M-D-as-Chief-Medical-Officer.html
https://www.globenewswire.com//news-release/2024/03/11/2843809/0/en/TransCode-Therapeutics-and-Akribion-Genomics-Report-Progress-Developing-CRISPR-Derived-Technology-for-Cancer-Treatment.html